Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Met@MPDA rejuvenates BMSC energy metabolism to promote bone regeneration in semaglutide-treated obese periodontitis

Jiang T., Wan TH., Wang MJ., Zhu XQ., Jiang YR., Yang F.

Animal Study on Chronic Inflammation, published in Mater Today Bio (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Mater Today Bio (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42182879
PMCID
PMC13197780
DOI
10.1016/j.mtbio.2026.103231

Abstract (original English)

Obesity is closely linked to periodontitis development. Although semaglutide is increasingly used to manage obesity, its effects on alveolar bone repair in periodontitis are not well understood. In a mouse model of obesity-related periodontitis, we found that obesity exacerbates alveolar bone loss in an inflammatory setting. Semaglutide treatment slightly reduced periodontal inflammation and osteoclast markers but did not improve osteogenesis or regenerate alveolar defects. Transcriptomic analysis revealed increased fatty-acid uptake but suppressed AMPK signaling and reduced fatty-acid oxidation (FAO) in inflamed alveolar bone of obese mice. In vitro , macrophage FAO was largely unaffected by inflammation or semaglutide, while FAO in bone marrow-derived mesenchymal stem cells (BMSCs) was significantly reduced, impairing osteogenic differentiation. To tackle metabolic and osteogenic issues, we created a metformin-loaded mesoporous polydopamine system (Met@MPDA) that acts as an AMPK agonist. Met@MPDA is absorbed by BMSCs, restoring cellular energy and promoting alveolar bone regeneration in periodontitis. While semaglutide provides anti-inflammatory benefits in obesity-related periodontitis, it falls short in boosting bone regeneration due to metabolic issues in BMSCs. Thus, Met@MPDA's sustained metformin delivery could enhance bone regeneration in these cases.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research